FLOVENT Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Flovent, and what generic alternatives are available?
Flovent is a drug marketed by Glaxosmithkline and Glaxo Grp Ltd and is included in four NDAs. There is one patent protecting this drug.
The generic ingredient in FLOVENT is fluticasone propionate. There are twenty-nine drug master file entries for this compound. Seventy-eight suppliers are listed for this compound. Additional details are available on the fluticasone propionate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Flovent
A generic version of FLOVENT was approved as fluticasone propionate by FOUGERA PHARMS on May 14th, 2004.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for FLOVENT?
- What are the global sales for FLOVENT?
- What is Average Wholesale Price for FLOVENT?
Summary for FLOVENT
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 4 |
Raw Ingredient (Bulk) Api Vendors: | 86 |
Clinical Trials: | 38 |
Patent Applications: | 5,456 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for FLOVENT |
Drug Sales Revenues: | Drug sales revenues for FLOVENT |
What excipients (inactive ingredients) are in FLOVENT? | FLOVENT excipients list |
DailyMed Link: | FLOVENT at DailyMed |
![FLOVENT drug patent expirations Drug patent expirations by year for FLOVENT](/p/graph/s/t/FLOVENT-patent-expirations.png)
![Drug Prices for FLOVENT](/p/graph/drug-price/FLOVENT.png)
![Drug Sales Revenue Trends for FLOVENT](/p/graph/drug-sales-revenues/FLOVENT.png)
Recent Clinical Trials for FLOVENT
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Glenmark Pharmaceuticals Ltd. India | Phase 3 |
Children's Hospital Medical Center, Cincinnati | Phase 2 |
Respirent Pharmaceuticals Co Ltd. | Phase 1 |
US Patents and Regulatory Information for FLOVENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | FLOVENT | fluticasone propionate | AEROSOL, METERED;INHALATION | 020548-001 | Mar 27, 1996 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxo Grp Ltd | FLOVENT DISKUS 100 | fluticasone propionate | POWDER;INHALATION | 020833-002 | Sep 29, 2000 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxosmithkline | FLOVENT | fluticasone propionate | POWDER;INHALATION | 020549-001 | Nov 7, 1997 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Glaxo Grp Ltd | FLOVENT HFA | fluticasone propionate | AEROSOL, METERED;INHALATION | 021433-001 | May 14, 2004 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for FLOVENT
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxosmithkline | FLOVENT | fluticasone propionate | POWDER;INHALATION | 020549-002 | Nov 7, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | FLOVENT | fluticasone propionate | POWDER;INHALATION | 020549-003 | Nov 7, 1997 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | FLOVENT | fluticasone propionate | AEROSOL, METERED;INHALATION | 020548-001 | Mar 27, 1996 | ⤷ Sign Up | ⤷ Sign Up |
Glaxosmithkline | FLOVENT | fluticasone propionate | AEROSOL, METERED;INHALATION | 020548-003 | Mar 27, 1996 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for FLOVENT
See the table below for patents covering FLOVENT around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Ireland | 810282 | ⤷ Sign Up | |
Austria | 395428 | ⤷ Sign Up | |
Spain | 8305379 | ⤷ Sign Up | |
Slovakia | 278140 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for FLOVENT
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1305329 | SPC/GB08/026 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: FLUTICASONE FUROATE AND SOLVATES THEREOF; REGISTERED: UK EU/1/07/434/001 20080116; UK EU/1/07/434/002 20080116; UK EU/1/07/434/003 20080116 |
2506844 | SPC/GB18/020 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117 |
2506844 | 1890025-8 | Sweden | ⤷ Sign Up | PRODUCT NAME: COMBINATION OF A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF (E.G. VILANTEROL TRIFENATATE) AND FLUTICASONE FUROATE.; REG. NO/DATE: EU/1/17/1236 20171117 |
2506844 | LUC00077 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |